10/2/2013 9:59:30 AM
CAMBRIDGE, Mass., Oct. 1, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced a poster presentation featuring preclinical data for its uridine nucleotide prodrug candidate for the treatment of hepatitis C virus (HCV) infection at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place in Washington, DC, November 1-5, 2013. Full abstracts can now be viewed at the AASLD website at www.aasld.org.
Help employers find you! Check out all the jobs and post your resume.
comments powered by